Replay available

Vertex Pharmaceuticals Incorporated (VRTX) Q2 2026 Earnings Call

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) Q2 2026 earnings conference call, held 2026-08-03. Replay captured from the company's public earnings webcast.

Mon, August 3, 2026 at 4:30 PMendedReplay
Vertex Pharmaceuticals Incorporated (VRTX) Q2 2026 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Susie Lisa

Senior Vice President of Investor Relations

Reshma Kewalramani

CEO and President

Duncan McKechnie

Chief Commercial Officer

Charlie Wagner

Chief Operating Officer and Chief Financial Officer

Replay transcript excerpt

Good day and welcome to the Vertex Pharmaceuticals second quarter 2026 earnings call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then 1 on your touchtone phone. And to withdraw your question, please press star then 2. Please note this event is being recorded. I would now like to turn the conference over to Ms. Susie Lisa. Please go ahead. Good evening, all. My name is Susie Lisa, and as the Senior Vice President of Investor Relations, it is my pleasure to welcome you to our second quarter 2026 Financial Results Conference call. On tonight's call, making prepared remarks, we have Dr. Reshma Kewalramani, Vertex's CEO and President, Charlie Wagner, Chief Operating Officer and Chief Financial Officer, and Duncan McKechnie, Chief Commercial Officer. We recommend that you access the webcast slides as you listen to this call. The call is being recorded and a replay will be available on our website. We will make forward-looking statements on this call that are subject to the risks and uncertainties discussed in detail in today's press release and in our filings with the Securities and Exchange Commission. Our pipeline, the proposed acquisition of Krenetics Pharmaceuticals and the expected benefits of that transaction, and Vertex's future financial performance are based on management's current assumptions. Actual outcomes and events could differ materially. I would also note that select financial results and guidance that we will review on the call this evening are presented on a non-GAAP basis. I'll now turn the call over to Reshma. Thanks, Susie. Good...

More from Vertex Pharmaceuticals Incorporated